SELLAS Life Sciences Group, Inc. (SLS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.22M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 0.00 USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.22M | (m) | $0.00 | (m) | (m) | (m) |
| 2026-03-31 | $-31.46M | (m) | $0.00 | (m) | (m) | (m) |
| 2025-12-31 | $-28.27M | (m) | $0.00 | (m) | $12.25M | (m) |
| 2025-09-30 | $-26.94M | (m) | $0.00 | (m) | $11.21M | (m) |
| 2025-06-30 | $-27.18M | (m) | $0.00 | (m) | $11.31M | (m) |
| 2025-03-31 | $-27.93M | (m) | $0.00 | (m) | $10.74M | (m) |
| 2024-12-31 | $-31.51M | (m) | $0.00 | (m) | $12.42M | (m) |
| 2024-09-30 | $-32.77M | (m) | $0.00 | (m) | $13.02M | (m) |
| 2024-06-30 | $-34.80M | (m) | $0.00 | (m) | $13.60M | (m) |
| 2024-03-31 | $-36.23M | (m) | $0.00 | (m) | $14.29M | (m) |
| 2023-12-31 | $-37.87M | $0.00 | $0.00 | (m) | $13.86M | (m) |
| 2023-09-30 | $-39.14M | $0.00 | $0.00 | (m) | $14.38M | (m) |
| 2023-06-30 | $-36.92M | $0.00 | $0.00 | (m) | $13.70M | (m) |
| 2023-03-31 | $-36.50M | $0.00 | $0.00 | (m) | $13.66M | (m) |
| 2022-12-31 | $-41.95M | $1.00M | $100.00K | (m) | $12.58M | -4195.00% |
| 2022-09-30 | $-44.12M | $1.00M | $100.00K | (m) | $11.51M | -4412.30% |
| 2022-06-30 | $-43.95M | $1.00M | $100.00K | (m) | $11.08M | -4395.40% |
| 2022-03-31 | $-39.78M | $2.90M | $200.00K | (m) | $10.78M | -1371.86% |
| 2021-12-31 | $-25.29M | $7.60M | $200.00K | $15.67M | $11.32M | -332.82% |
| 2021-09-30 | $-17.83M | $9.50M | (m) | $15.05M | $12.08M | -187.73% |
| 2021-06-30 | $-15.35M | $9.50M | (m) | $12.88M | $11.77M | -161.57% |
| 2021-03-31 | $-15.16M | $7.60M | (m) | $11.70M | $10.96M | -199.51% |
| 2020-12-31 | $-16.98M | $1.90M | (m) | $9.28M | $9.60M | -893.79% |
| 2020-09-30 | (m) | (m) | (m) | $8.76M | $8.71M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $8.19M | $8.97M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $7.29M | $9.62M | (m) |
| 2019-12-31 | $-20.04M | $0.00 | (m) | $7.29M | $9.92M | (m) |
| 2017-12-31 | $-23.04M | (m) | (m) | $6.07M | $15.09M | (m) |
| 2017-09-30 | $-21.60M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-23.61M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-27.99M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-31.87M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-32.32M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-34.48M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-34.28M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-34.22M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-44.65M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-46.98M | $10.95M | (m) | (m) | (m) | -429.20% |
| 2015-03-31 | $-51.50M | $9.90M | (m) | (m) | (m) | -520.40% |
| 2014-12-31 | $-52.22M | $9.32M | (m) | (m) | (m) | -560.38% |
| 2014-09-30 | $-53.19M | $7.44M | (m) | (m) | (m) | -714.82% |
| 2014-06-30 | $-46.88M | $6.99M | (m) | (m) | (m) | -670.50% |
| 2014-03-31 | $-39.08M | $4.66M | (m) | (m) | (m) | -838.58% |
| 2013-12-31 | $-33.84M | $2.49M | (m) | (m) | (m) | -1360.68% |
| 2013-09-30 | (m) | (m) | (m) | $18.05M | (m) | (m) |
| 2013-06-30 | (m) | $0.00 | (m) | $18.59M | (m) | (m) |
| 2013-03-31 | (m) | $0.00 | (m) | $17.03M | (m) | (m) |
| 2012-12-31 | $-21.20M | $0.00 | (m) | $14.61M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | $12.65M | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | $9.85M | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | $4.36M | (m) | (m) |
| 2011-12-31 | $-12.49M | $0.00 | (m) | $3.85M | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |